Testing a new blood cancer treatment for patients whose previous therapy stopped working

This study is testing pirtobrutinib, an oral medication, in people with chronic lymphocytic leukemia or small lymphocytic lymphoma (types of blood cancers) whose disease has come back or stopped responding to previous treatments. The trial will test three different doses of the medication to see which works best and has the fewest side effects. This treatment works differently than some older medications, which may help patients whose cancer has become resistant to standard therapies.

Many patients with these blood cancers eventually develop resistance to current treatments, leaving them with limited options. This medication represents a new approach that may work even when other therapies have stopped being effective, potentially giving patients another chance at controlling their disease.